“The main message we need to convey is that with the development of advanced systemic treatments (chemotherapy and radiotherapy) patients with non-metastatic LAPC have increased chance for surgery and, therefore, increased chance for improved survival,” said Dr. Georgios Gemenetzis from Johns Hopkins University School of Medicine in Baltimore, Maryland. Read more here . . .
In highly selected patients with locally advanced pancreatic cancer (LAPC), surgical resection after neoadjuvant therapy is feasible and associated with longer overall survival, researchers report.